August 14, 2023 4:56pm
Still not out of the dark earnings’ release forest of fallen share pricing
News: FDA puts 2seventy bio’s (TSVT) CAR-T clinical trial (bluebird bio (BLUE) spin-out) on formal hold after patient death
Pre-Open Indication: 1 Hit and 2 Miss
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Never leave an investor uninformed!
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-military officer and x-FBI, an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to our knowledge of price movements and questioning pricing targets.
The Dow closed UP +26.23 or +0.07%, the S&P closed UP +25.67 or +0.58% while the Nasdaq closed UP +143.48 points (+1.05%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes rose after being up and down yet, closing positive.
The moves come as stocks have struggled to sustain their 2023 rally in the late summer. Last week, the S&P 500 fell -0.03% and Nasdaq dropped -1.9%.
Monday (8/14) … RegMed Investors’ (RMi) Opening Bell: “Investors should be holding pat, there are a few buy ops … https://www.regmedinvestors.com/articles/13076
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …
- Monday’s advance/decline line opened negative at 6 up/ 27 down and 2 flats, stayed negative with 11 up/ 21 down and 3 flats at the mid-day, ending with a negative close of 16 incliners, 18 decliners and 1 flat
Pre-Open Indications: 1 Hits < (BLFS +$0.46)> and 2 Miss <BEAM -$0.33, CRSP -$1.23)>
52-Week Lows:
- Sangamo Therapeutics (SGMO) at $1.02
- Fate Therapeutics (FATE) at $3.02
Ebb and flow:
- Q3: August – 2 positives and 8 negative closes
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
Monday, the IBB was down -0.12% and the XBI was up +0.20%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was down -0.07 point or -0.47% at 14.77
Closing Down (10 of 18):
- Alnylam Pharmaceuticals (ALNY -$4.44)
- CRISPR Therapeutics (CRSP -$1.23)
- Verve Therapeutics (VERV -$0.91),
- Intellia Therapeutics (NTLA -$0.59),
- Ionis Pharmaceuticals (IONS -$0.34),
- Beam Therapeutics (BEAM -$0.33),
- Caribou Bioscience (CRBU -$0.25),
- Sage therapeutics (SAGE -$0.14),
- Graphite Bio (GRPH +$0.12),
- Adverum Biotechnologies (ADVM -$0.10),
Flat (1):
- Harvard Apparatus RM (HRGN)
Closing Up (10 of 16):
- Blueprint Medicine (BPMC +$1.88),
- Ultragenyx Pharmaceuticals (RARE +$1.58),
- Prime Medicine (PRME +$0.54),
- BioLife Solutions (BLFS +$0.46),
- Regenxbio (RGNX +$0.34),
- Generation Bio (GBIO +$0.20),
- bluebird bio (BLUE+-$0.20),
- Voyager Therapeutics (VYGR +$0.15),
- Precigen (PGEN +$0.12),
- Solid Biosciences (SLDB +$0.11)
Q3/23 – August
- Monday closed negative with 16 incliners, 18 decliners and 1 flat
The BOTTOM LINE: I try to keep it simple … and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Indexes closed higher Monday, as the cell and gene therapy sector was unable to shake off a rough August so far.
Meanwhile, eyes will also be on the release of the minutes from the Federal Reserve's last policy meeting, in which the central bank resumed its rate-hike campaign. Wall Street will be keen to decipher any clues in the minutes that point to the Fed's next move in September. <Yahoo Finance>
August tends to frighten many stock market investors and historians.
· The stock market is riding high after a strong performance in July, but August could be a difficult month for investors.
· Data compiled by the Stock Trader’s Almanac shows the S&P 500 averages just a 0.1% gain in August. That makes it the third-worst month on average for the benchmark index. The Dow, meanwhile, averages a loss of 0.04% in August. <CNBC>
Cell and gene therapy sector performance continues earning season…
Three (3) more releases today – Homology Medicine (FIXX), Brainstorm Cell Therapeutics (BCLI) and Harvard Apparatus RM )HRGN – formerly – failed - Biostage (BSTG) – still all but broke!
Q2/23 net losses earnings, cash positions and runway outcomes. LPS (loss-per-share) releases will present challenges to share pricing with outcomes included … https://www.regmedinvestors.com/articles/13058
Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
Some Bad News: bluebird bio’s (BLUE) spin-out FDA puts 2seventy bio’s (TSVT) CAR-T clinical trial on formal hold after patient death
· TSVT announced Monday with its Q2 earnings that the regulator has officially halted the P1 study after a child with acute myeloid leukemia died following treatment.
The top three (3) performing in the session:
Monday: Blueprint Medicine (BPMC), Ultragenyx (RARE) and Prime Medicine (PRME)
While The worst three (3) in the session:
Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Verve Therapeutics (VERV)
I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.
The NO spin zone! U.S. public shareholders deserve accountability …
Harvard Apparatus Regenerative Technology (HRGN) formerly Biostage (OTCQB: BSTG) … as of 7/20/23 -- so many issues!
· Question: is HRGN just another Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?
· Accumulated deficit: $85,901 M
· Will HRGN ESCAPE the scandals when its “former” corporate name was used by a former chairman and CEO Green initiating scandal plagued utilization of an Italian surgeon and the $5 M it took to settle out the executive responsibility as it was SHIFTED to the company shareholders and Harvard Bio (HBIO)???
· Can this management team be TRUSTED by ANY shareholder other then major holders’ Chinese off-shore investors.
· HRGN schedules earnings LPS (loss-per-share) release an SHORT runway as 3 - 5 year trial begins
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
